Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1345)	1/30/1998 11:30:00 AM
From: Rick Costantino	Read Replies (2) \| Respond to of 2205

Marshall, It seems like along time since I started this thread, and I remember you were one of the first to repsond. It looks us long-termers have been vindicated, at least to some extent, and there is probably some more good days ahead. I am a bit curious as to why we haven't seen more of a rise here. I remember days where we were pushing $20, and I highly suspect we will see that again soon. But this probably has a lot to do with analysts' views (remember there is still a sell recommendation out, which I bet will soon change), the pressure put on by the shorts, etc. But these are factors which have little to do with ATIS's technology. I think the panel's recommendation has finally silenced the critics and soon ATIS will be one of the first companies to commercialize an engineering human tissue product. We are truly on the verge of a historic moment in biotechnology. Aside from our (admittedly) greedy interest, let's not forget the reduction in suffering this product can accomplish, and that the door has been opened for other life-enhancing products from tissue engineering. For example, I was extremely pleased to see the recent approval of Rituxan, the first recombinant immunoglobulin for a cancer indication, which has opened the door for a number of other antibodies for other cancer indications in early-to-late stage clinical trials. Money is not the only compensation. It is an added bonus to know that one is investing in the technology to satisfy unmet medical needs and improve the quality of life. Rick C